Get the Stockscreener App
5.70
1.38%
-0.08
After Hours:
5.61
-0.09
-1.58%
Maravai Lifesciences Holdings Inc stock is traded at $5.70, with a volume of 2.38M.
It is down -1.38% in the last 24 hours and down -12.44% over the past month.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
See More
Previous Close:
$5.78
Open:
$5.72
24h Volume:
2.38M
Relative Volume:
0.86
Market Cap:
$849.24M
Revenue:
$204.73M
Net Income/Loss:
$-184.29M
P/E Ratio:
-7.8882
EPS:
-0.7226
Net Cash Flow:
$-51.87M
1W Performance:
-8.51%
1M Performance:
-12.44%
6M Performance:
+92.57%
1Y Performance:
+119.23%
1-Day Range:
$5.55
$5.82
1-Week Range:
$5.55
$6.35
52-Week Range:
$2.28
$7.44
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Name
Maravai Lifesciences Holdings Inc
Sector
Industry
Phone
(858) 546-0004
Address
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
5.70 | 861.16M | 204.73M | -184.29M | -51.87M | -0.7226 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-19-24 | Initiated | Guggenheim | Neutral |
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Aug-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-10-24 | Initiated | Craig Hallum | Buy |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-08-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| May-23-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-09-23 | Downgrade | Goldman | Buy → Neutral |
| Jan-05-23 | Downgrade | UBS | Buy → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-22 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Dec-16-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-15-20 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Initiated | Credit Suisse | Outperform |
| Dec-15-20 | Initiated | Goldman | Buy |
| Dec-15-20 | Initiated | Jefferies | Buy |
| Dec-15-20 | Initiated | Robert W. Baird | Outperform |
| Dec-15-20 | Initiated | Stifel | Buy |
| Dec-15-20 | Initiated | William Blair | Outperform |
| Dec-14-20 | Initiated | UBS | Buy |
View All
Maravai Lifesciences Holdings Inc Stock (MRVI) Latest News
Wall Street Zen Upgrades Maravai LifeSciences (NASDAQ:MRVI) to Buy - marketbeat.com
Maravai (MRVI) Q2 2026 Earnings Call Transcript - AOL.com
Maravai LifeSciences (MRVI) group reports 4.0M shares, 2.72% beneficial stake - Stock Titan
Dimensional Fund Advisors LP Boosts Holdings in Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat
Maravai LifeSciences (NASDAQ:MRVI) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Maravai Q2 2026 slides: margin expansion drives EBITDA guidance raise By Investing.com - Investing.com Nigeria
Maravai LifeSciences (MRVI) Releases Q2 2026 Earnings: Revenue Beats Estimates and Loss Narrows - Quiver Quantitative
Deutsche Bank Adjusts Maravai Lifesciences PT to $8 From $6, Maintains Buy Rating - Moomoo
Maravai LifeSciences Holdings, Inc. (MRVI) stock price, news, quote and history - Yahoo Finance Singapore
MRVI Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $6.50 - GuruFocus
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap DownHere's What Happened - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Maravai LifeSciences (NASDAQ:MRVI) Stock Price - marketbeat.com
Maravai LifeSciences posts investor presentation on mRNA, gene editing, cell and gene therapy tools platform - Bitget
Earnings call transcript: Maravai LifeSciences beats Q2 2026 estimates, shares fall - Investing.com South Africa
Maravai LifeSciences Holdings (MRVI) Stock Analysis: Navigating Challenges with Biotech Innovation - DirectorsTalk Interviews
MRVI Looks 63.2% Overvalued on GF Value™ - GuruFocus
Is Maravai LifeSciences (MRVI) Overvalued After Q2 Earnings Miss? GF Score: 61/100 - GuruFocus
Maravai LifeSciences Holdings, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Maravai LifeSciences Q2 Earnings Call Highlights - finance.yahoo.com
Maravai LifeSciences Holdings Inc (MRVI) (Q2 2026) Earnings Call - GuruFocus
Levi & Korsinsky Notifies Maravai LifeSciences Holdings, Inc. Inv - The National Law Review
Maravai LifeSciences Holdings, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:MRVI) 2026-08-06 - Seeking Alpha
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Maravai LifeSciences Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Q2 2026 Maravai LifeSciences Holdings Inc Earnings Call Transcript - GuruFocus
MRVI: Q2 revenue up 9% to $51.4M; EBITDA guidance raised on margin expansion confidence - TradingView
MRVI: Revenue and margins rose sharply in H1 2026, with net loss narrowing and debt refinanced - TradingView
Maravai LifeSciences Reports Second Quarter 2026 Financial Results - Yahoo Finance
Maravai Lifesciences in focus: Can Q1 momentum hold in earnings? - Investing.com
Maravai Lifesciences in focus: Can Q1 momentum hold in earnings? By Investing.com - Investing.com Nigeria
Maravai Lifesciences Holdings Inc (NASDAQ: MRVI) Stock Price, News & Analysis - Kalkine
Maravai Q2 2026 slides: margin surge amid operational turnaround - Investing.com
Maravai LifeSciences Holdings Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results - The National Law Review
Lazard Asset Management LLC Sells 170,919 Shares of Maravai LifeSciences Holdings, Inc. $MRVI - marketbeat.com
Maravai LifeSciences (NASDAQ:MRVI) Downgraded by Wall Street Zen to Hold - marketbeat.com
Maravai LifeSciences (MRVI) Expected to Announce Earnings on Thursday - marketbeat.com
Maravai LifeSciences Holdings Inc - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Cash Flow - TradingKey
MRVI|Maravai LifeSciences Holdings Inc|Price:6.760|Chg%:-0.290 - TradingKey
TradingKey - TradingKey
MRVI|Maravai LifeSciences Holdings Inc|Price:6.690|Chg%:-0.070 - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Maravai LifeSciences Holdings, Inc. Revenue Breakdown – NASDAQ:MRVI - TradingView
Maravai Lifesciences Holdings, Inc. (MRVI) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Maravai Lifesciences Holdings, Inc. (MRVI) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Maravai LifeSciences(MRVI) Stock Options Chain | Quotes & News - Moomoo
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences - The National Law Review
Maravai LifeSciences to announce Q2 results on August 6 - scanx.trade
Maravai Lifesciences Holdings Inc Stock (MRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):